{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:08:12Z","timestamp":1746331692680,"version":"3.40.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T00:00:00Z","timestamp":1674777600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,27]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>The coexistence of the extranidal marginal zone lymphoma (MZL) of mucosa\u2013associated lymphoid tissue (MALT) and multiple myeloma (MM) is an exceedingly rare situation. The rare situation precludes any evidence-based guidelines for MZL or MM.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns and diagnoses:<\/jats:title>\n            <jats:p>We presented a unique case of the coexistence of primary mediastinal MALT lymphoma and MM like polyneuropathy, organomegaly, endocrinopathy, M-protein, skin syndrome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions and outcomes:<\/jats:title>\n            <jats:p>The patient was first diagnosed with polyneuropathy, organomegaly, endocrinopathy, M-protein, skin syndrome in the department of neurology, then MM in the department of hematology, and the mediastinal MALT simultaneously coexisting with MM was found by biopsy in the department of thoracic surgery. The patient received combination therapy with rituximab and bortezomib followed by lenalidomide maintenance. To understand MZL lymphoma with plasmacytic differentiation better, we analyzed cases of MZL lymphomas with plasma cell neoplasms. Most of these cases were MZL lymphomas with light chain-restricted plasmacytic differentiation. The lymphomas relapsed with plasma cell neoplasms or transformed into plasma cell neoplasms after anti-lymphoma therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>The case demonstrated clinical complexity and the importance of the detailed assessment. The case and literature review demonstrated the value of detecting light chain-restricted plasmacytic differentiation for the treatment of MZL lymphoma with rituximab plus lenalidomide or bortezomib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032801","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T22:17:50Z","timestamp":1676413070000},"page":"e32801","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Coexistence of primary mediastinal MALT lymphoma and multiple myeloma like POEMS syndrome: A case report and literature review"],"prefix":"10.1097","volume":"102","author":[{"given":"Shangjin","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"},{"name":"Department of Hematology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Yunyan District, Guiyang City, Guizhou Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuangguo","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duanhao","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-7077","authenticated-orcid":false,"given":"Wei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/PAP.0000000000000305","article-title":"Mediastinal lymphoproliferative disorders.","volume":"28","author":"Pina-Oviedo","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review.","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/blood-2002-07-2299","article-title":"POEMS syndrome: definitions and long-term outcome.","volume":"101","author":"Dispenzieri","year":"2003","journal-title":"Blood"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp-2020-324012","article-title":"Early VEGF testing in inflammatory neuropathy avoids POEMS syndrome misdiagnosis and associated costs.","volume":"92","author":"Marsh","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.4103\/0973-1482.172123","article-title":"An atypical presentation of POEMS syndrome with IgG kappa type M protein and normal VEGF level: case report and review of literature.","volume":"14","author":"Pulivarthi","year":"2018","journal-title":"J Cancer Res Ther"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1007\/s10072-021-05583-7","article-title":"Paraproteinemia and neuropathy.","volume":"42","author":"Koike","year":"2021","journal-title":"Neurol Sci"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/JTO.0b013e3181c07df8","article-title":"Primary thymic mucosa-associated lymphoid tissue lymphoma: diagnostic tips.","volume":"5","author":"Shimizu","year":"2010","journal-title":"J Thorac Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.anndiagpath.2008.04.010","article-title":"Systemic CD5+ MALT lymphoma: presentation with Waldenstrom syndrome.","volume":"13","author":"Mikolaenko","year":"2009","journal-title":"Ann Diagn Pathol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/keh248","article-title":"Combined therapy with rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) for Sj\u00f6gren\u2019s syndrome-associated B-cell aggressive non-Hodgkin\u2019s lymphomas.","volume":"43","author":"Voulgarelis","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3988\/jcn.2015.11.3.283","article-title":"Autoantibody-mediated sensory polyneuropathy associated with indolent B-Cell Non-Hodgkin\u2019s lymphoma: a report of two cases.","volume":"11","author":"St\u00fcbgen","year":"2015","journal-title":"J Clin Neurol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdm375","article-title":"Pathology and clinical course of MALT lymphoma with plasmacytic differentiation.","volume":"18","author":"W\u00f6hrer","year":"2007","journal-title":"Ann Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e29219","DOI":"10.1097\/MD.0000000000029219","article-title":"Coexistence of nodal marginal zone B-cell lymphoma and multiple myeloma: a case report and literature review.","volume":"101","author":"Wang","year":"2022","journal-title":"Medicine (Baltim)"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00019606-200406000-00003","article-title":"A common clonal origin of nodal marginal zone B-cell lymphoma and plasma cell myeloma demonstrating different immunophenotypes: a case report of composite lymphoma.","volume":"13","author":"Saito","year":"2004","journal-title":"Diagn Mol Pathol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s00277-004-0870-y","article-title":"Concomitant occurrence of MALT lymphoma and multiple myeloma.","volume":"83","author":"W\u00f6hrer","year":"2004","journal-title":"Ann Hematol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-018-3300-2","article-title":"Histological transformation of MALT lymphoma to plasma cell leukemia after rituximab-containing therapy.","volume":"97","author":"Suzuki","year":"2018","journal-title":"Ann Hematol"},{"key":"R16-20250504","first-page":"703","article-title":"Transformation of MALT lymphoma to pure plasma cell histology: possible association with anti-CD20 antibody treatment.","volume":"11","author":"Noa","year":"2009","journal-title":"Isr Med Assoc J"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/10428190500178399","article-title":"Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab.","volume":"46","author":"Woehrer","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00277-016-2751-6","article-title":"Extraosseous plasmacytoma in the nasal cavity after rituximab therapy against pulmonary MALT lymphoma.","volume":"95","author":"Nakamura","year":"2016","journal-title":"Ann Hematol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance.","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1186\/s12903-021-01960-y","article-title":"Primary oral mucosa-associated lymphoid tissue (MALT) lymphoma in patient with monoclonale gammopathy: a rare case report.","volume":"21","author":"Hafian","year":"2021","journal-title":"BMC Oral Health"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","article-title":"A phase II study of bortezomib in patients with MALT lymphoma.","volume":"94","author":"Troch","year":"2009","journal-title":"Haematologica"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/blood-2013-05-503862","article-title":"Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).","volume":"122","author":"Dimopoulos","year":"2013","journal-title":"Blood"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.15843","article-title":"Lenalidomide plus rituximab (R2) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.","volume":"185","author":"Becnel","year":"2019","journal-title":"Br J Haematol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2012.065995","article-title":"A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma).","volume":"98","author":"Kiesewetter","year":"2013","journal-title":"Haematologica"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40273-020-00971-x","article-title":"Lenalidomide with Rituximab for previously treated follicular lymphoma and marginal zone lymphoma: an evidence review group perspective of a NICE single technology appraisal.","volume":"39","author":"Witlox","year":"2021","journal-title":"PharmacoEcon"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032801","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:05:16Z","timestamp":1746324316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,27]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032801","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,1,27]]}}}